AstraZeneca’s breast cancer drug fails major trial after FDA approval
- AstraZeneca’s breast cancer drug camizestrant failed to meet the main goal in a late-stage clinical trial.
- The Phase 3 SERENA-4 trial involved 1,371 patients with previously untreated advanced breast cancer.
- Camizestrant showed a numerical improvement in delaying cancer progression, but the result was not statistically significant.
- The result came days after the US FDA approved the drug for a specific group with ESR1-mutated advanced breast cancer, based on another trial.
Source: ndtv.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
